izpis_h1_title_alt

Cathepsin C : structure, function, and pharmacological targeting
ID Stojkovska, Milena (Avtor), ID Novinec, Marko (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (1,89 MB)
MD5: 10021AB84E4999F03112C483601D1288
URLURL - Izvorni URL, za dostop obiščite https://rdodjournal.com/article/view/5974 Povezava se odpre v novem oknu

Izvleček
Cathepsin C is a papain-like cysteine peptidase known primarily for its involvement in the activation of serine peptidases in neutrophils and other immune cells. Its critical role in this process qualifies cathepsin C as a target for the treatment of inflammatory diseases, and its most advanced inhibitor, brensocatib (Insmed), is currently in phase 3 clinical trials for the treatment of non-cystic fibrosis bronchiectasis. Beyond neutrophils, its importance is highlighted by loss-of-function mutations that cause the recessively inherited Papillon-Lefèvre syndrome. At the molecular level, cathepsin C has several structural and functional features that set it apart from other members of the family and enable its selective targeting. It possesses dipeptidyl-peptidase activity (its other common name is dipeptidyl-peptidase I) due to the presence of an additional exclusion domain that also controls its stepwise tetramerization during maturation. In this review article, we summarize the current state of the art regarding the biochemical properties of cathepsin C, its physiological and pathological roles in neutrophils and beyond, and recent advances in the development and evaluation of cathepsin C inhibitors.

Jezik:Angleški jezik
Ključne besede:dipeptidyl-peptidase I, DPPI, cysteine catepsin, bronchiectasis, brensocatib
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:FKKT - Fakulteta za kemijo in kemijsko tehnologijo
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Datum objave:01.01.2023
Leto izida:2023
Št. strani:Str. 1-17
Številčenje:Vol. 2, iss. 3, art. 14
PID:20.500.12556/RUL-148208 Povezava se odpre v novem oknu
UDK:547.112
ISSN pri članku:2771-2893
DOI:10.20517/rdodj.2023.09 Povezava se odpre v novem oknu
COBISS.SI-ID:160356355 Povezava se odpre v novem oknu
Datum objave v RUL:02.08.2023
Število ogledov:777
Število prenosov:58
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Rare disease and orphan drugs journal
Skrajšan naslov:Rare dis. orphan drug j.
Založnik:OAE Publishing Inc.
ISSN:2771-2893
COBISS.SI-ID:160332035 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:dipeptidil-peptidaza I, DPPI, cisteinski katepsin, bronhiektazija, brensocatib

Projekti

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:N1-0211
Naslov:Uvedba kooperativnosti v peptidaze za izboljšanje njihove aktivnosti in uravnavanja

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P1-0179
Naslov:Napredna organska sinteza in kataliza

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj